Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

For almost 60 years, scientists have tried to understand why DNA doesn't replicate wildly and uncontrollably every time a ...

Varun Venkataramani is the winner of the 2025 Eppendorf Award for Young European Investigators. A neurologist and group leader at Heidelberg University Hospital, Germany, his work in cancer ...

Researchers at Moffitt Cancer Center have developed a new way to predict how cancer cells evolve by gaining and losing whole ...

New study shows that aggressive cancer cells can be identified in a simple, new way; by how they physically behave, not just by their genes. Using specially textured Meta surfaces pattered with tiny ...

A new study reveals a simple and fast, label-free way to distinguish aggressive cancer cells by how they physically behave.

Tumours have developed many strategies and tricks to gain advantages in the body. Led by cell biology professor Sabine Werner, researchers at ETH Zurich have now discovered another surprising trick ...

Scientists are looking for answers about how these confounding trips, known as metastases, occur throughout the human body Illustration of a human cancer cell Amber Dance, Knowable Magazine Back in ...

Cancer and Alzheimer’s disease rarely strike the same person, a pattern that has puzzled clinicians for years. Instead of ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...